D. Wingerchuk

发表

A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.

Hans Lassmann, Joseph E Parisi, J. Parisi, 2002, Brain : a journal of neurology.

B. Weinshenker, D. Wingerchuk, Dean M Wingerchuk, 2003, Neurology.

Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial

R. Elashoff, D. Arnold, N. Sicotte, 2016, The Lancet Neurology.

The natural history of multiple sclerosis: a geographically based study: 8: familial multiple sclerosis.

J. Baskerville, A. Sadovnick, G. Rice, 2000, Brain : a journal of neurology.

Epidemiology and natural history of multiple sclerosis: new insights

O. Kantarci, D. Wingerchuk, Orhun Kantarci, 2006, Current opinion in neurology.

The clinical course of neuromyelitis optica (Devic’s syndrome)

P C O'Brien, P. O'Brien, B. Weinshenker, 1999, Neurology.

Active and progressive

B. Weinshenker, A. Cross, D. Wingerchuk, 2014, Neurology.

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Gary R Cutter, Friedemann Paul, Fred D Lublin, 2019, The Lancet.

Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders

Terry J. Smith, Jeffrey A. Cohen, Jacqueline Palace, 2021, Journal of Neurology.

Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension

K. Fujihara, Jacqueline A Palace, H. Kim, 2021, Multiple sclerosis.

AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.

H. Hartung, K. Fujihara, B. Weinshenker, 2021, Multiple sclerosis and related disorders.

Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD

F. Paul, H. Hartung, K. Fujihara, 2021, Multiple sclerosis.

Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis

S. Vukusic, B. Weinshenker, C. Lucchinetti, 2006, Annals of neurology.

Revised diagnostic criteria for neuromyelitis optica

B. Weinshenker, C. Lucchinetti, D. Wingerchuk, 2006, Neurology.

The spectrum of acute cardiopulmonary events associated with multiple sclerosis exacerbations

D. Wingerchuk, J. Carter, Cristina Valencia-Sanchez, 2019, Multiple sclerosis.

Genetic variation in the tumor necrosis factor alpha gene and the outcome of multiple sclerosis

D. Schaid, B. Weinshenker, S. Sommer, 1997, Neurology.

Neuromyelitis Spectrum Disorders

B. Weinshenker, D. Wingerchuk, 2017, Mayo Clinic proceedings.

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

A. Traboulsee, B. Banwell, W. Carroll, 2015, Neurology.

Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders

F. Paul, Su-Hyun Kim, H. Kim, 2018, Multiple sclerosis.

Seizure prophylaxis in patients with brain tumors: a meta-analysis.

M. Lyons, R. Zimmerman, J. Sirven, 2004, Mayo Clinic proceedings.

Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression.

B. Weinshenker, C. Lucchinetti, D. Wingerchuk, 2006, Archives of neurology.

Is there a neurologist on this flight?

R. Caselli, J. Sirven, J. Drazkowski, 2002, Neurology.

Does High Cerebral Microbleed Burden Increase the Risk of Intracerebral Hemorrhage After Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke?

B. Demaerschalk, D. Wingerchuk, D. Almader-Douglas, 2019, The neurologist.

Acute Basilar Artery Occlusion: Does Recanalization Improve Clinical Outcome? A Critically Appraised Topic

D. Wingerchuk, O. Dumitrascu, Cumara B. O’Carroll, 2018, The Neurologist.

Does Cervical Manipulative Therapy Cause Vertebral Artery Dissection and Stroke?

B. Demaerschalk, D. Wingerchuk, M. Miley, 2008, The neurologist.

Migraine with and without aura and risk for cardiovascular disease

D. Dodick, B. Demaerschalk, D. Wingerchuk, 2008, Current atherosclerosis reports.

Cerebral Venous Thrombosis Complicated by Hemorrhagic Infarction: Factors Affecting the Initiation and Safety of Anticoagulation

E. Wijdicks, J. Fulgham, D. Wingerchuk, 1998, Cerebrovascular Diseases.

Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder.

Terry J. Smith, S. Achard, Jacqueline Palace, 2015, JAMA neurology.

Does Prophylactic Postoperative Hypervolemic Therapy Prevent Cerebral Vasospasm and Improve Clinical Outcome After Aneurysmal Subarachnoid Hemorrhage?

B. Demaerschalk, D. Wingerchuk, M. Aguilar, 2008, The neurologist.

Smoking: effects on multiple sclerosis susceptibility and disease progression

D. Wingerchuk, 2012, Therapeutic advances in neurological disorders.

Restoring immune tolerance in neuromyelitis optica

J. M. Behne, Terry J. Smith, Jeffrey A. Cohen, 2016, Neurology: Neuroimmunology & Neuroinflammation.

Restoring immune tolerance in neuromyelitis optica

J. M. Behne, Terry J. Smith, Jeffrey A. Cohen, 2016, Neurology: Neuroimmunology & Neuroinflammation.

Are Postprocedural Blood Pressure Goals Associated With Clinical Outcome After Mechanical Thrombectomy for Acute Ischemic Stroke?

B. Chong, D. Wingerchuk, Cumara B. O’Carroll, 2019, The neurologist.

Environmental factors in multiple sclerosis: Epstein-Barr virus, vitamin D, and cigarette smoking.

D. Wingerchuk, 2011, The Mount Sinai journal of medicine, New York.

A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing–remitting multiple sclerosis

G. Rice, G. Ebers, D. Wingerchuk, 2005, Journal of Neurology, Neurosurgery & Psychiatry.

) for relapsing-remitting multiple sclerosis 3 Dstudy of oral calcitriol (1,25-dihydroxyvitamin

G. Rice, G. Ebers, D. Wingerchuk, 2005 .

Transient smartphone blindness: Relevance to misdiagnosis in neurologic practice

D. Wingerchuk, Saraniya Sathiamoorthi, 2017, Neurology.

Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders

B. Weinshenker, C. Lucchinetti, T. Kaufmann, 2016, Journal of Neurology, Neurosurgery & Psychiatry.

Acute Disseminated Encephalomyelitis, Transverse Myelitis, and Neuromyelitis Optica

B. Weinshenker, D. Wingerchuk, 2013, Continuum.

Does General Anesthesia Compared With Conscious Sedation Result in Better Outcomes in Acute Stroke Patients Undergoing Endovascular Therapy?

B. Bendok, B. Chong, B. Demaerschalk, 2021, The neurologist.

The Clinical Utility of High Resolution Magnetic Resonance Imaging in the Diagnosis of Giant Cell Arteritis: A Critically Appraised Topic

J. Hoxworth, B. Demaerschalk, D. Wingerchuk, 2008, The neurologist.

Amantadine for Patients With Severe Traumatic Brain Injury: A Critically Appraised Topic

B. Demaerschalk, D. Wingerchuk, K. Wellik, 2015, The Neurologist.

Epidemiology of neuromyelitis optica in the United States: a multicenter analysis.

D. Wingerchuk, M. Levy, B. Greenberg, 2012, Archives of neurology.

Predictive models in the diagnosis and treatment of autoimmune epilepsy

J. Britton, G. Cascino, E. Wirrell, 2017, Epilepsia.

Paraneoplastic encephalomyelitis and seminoma

J. Noseworthy, D. Wingerchuk, D. Kimmel, 1998, Neurology.

Does the Initiation of Fluoxetine Postacute Stroke Result in Improved Functional Recovery?

B. Demaerschalk, D. Wingerchuk, Cumara B. O’Carroll, 2021, The neurologist.

Skin Biopsy for Diagnosis of Small Fiber Neuropathy: A Critically Appraised Topic

B. Demaerschalk, D. Wingerchuk, Benn Smith, 2010, The neurologist.

Sniffing out Parkinson Disease: Can Olfactory Testing Differentiate Parkinsonian Disorders?

C. Adler, J. Caviness, B. Demaerschalk, 2007, The neurologist.

A secondary progressive clinical course is uncommon in neuromyelitis optica

B. Weinshenker, C. Lucchinetti, D. Wingerchuk, 2007, Neurology.

Restoring immune tolerance in neuromyelitis optica

J. M. Behne, Terry J. Smith, Jeffrey A. Cohen, 2016, Neurology: Neuroimmunology & Neuroinflammation.

In Patients With Melanoma Brain Metastases, Is Combination Immune Checkpoint Inhibition a Safe and Effective First-Line Treatment? A Critically Appraised Topic

M. Mrugala, D. Wingerchuk, Cumara B. O’Carroll, 2022, The neurologist.

Atraumatic Lumbar Puncture Needles: After All These Years, Are We Still Missing the Point?

K. Arendt, B. Demaerschalk, D. Wingerchuk, 2009, The neurologist.

Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions

J. Parisi, B. Weinshenker, C. Lucchinetti, 2015, Neurology.

Caffeine for the Prevention and Treatment of Postdural Puncture Headache: Debunking the Myth

D. Dodick, B. Demaerschalk, D. Wingerchuk, 2007, The neurologist.

Neuromyelitis Optica Spectrum Disorder.

C. Lucchinetti, D. Wingerchuk, 2022, The New England journal of medicine.

Update on biomarkers in neuromyelitis optica

J. P. Garrahan, Terry J. Smith, Jacqueline Palace, 2015, Neurology: Neuroimmunology & Neuroinflammation.

The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease

B. Weinshenker, D. Wingerchuk, 2012, Multiple sclerosis.

Neuromyelitis optica.

M. Morrow, D. Wingerchuk, 2012, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

Neuromyelitis Optica: Potential Roles for Intravenous Immunoglobulin

D. Wingerchuk, 2012, Journal of Clinical Immunology.

NEUROMYELITIS OPTICA SPECTRUM DISORDERS: DIAGNOSIS AND TREATMENT

D. Wingerchuk, Cme Questions, 2011 .

Neuromyelitis optica: clinical syndrome and the NMO-IgG autoantibody marker.

B. Weinshenker, D. Wingerchuk, 2008, Current topics in microbiology and immunology.

Neuromyelitis optica

B. Weinshenker, D. Wingerchuk, 2007, Current Treatment Options in Neurology.

Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG–Associated Disorders

B. Weinshenker, C. Lucchinetti, J. Tillema, 2018, JAMA neurology.

Second-generation antiepileptic drugs' impact on balance: a meta-analysis.

T. Fife, J. Sirven, J. Drazkowski, 2007, Mayo Clinic proceedings.

Is Noninvasive Vagus Nerve Stimulation a Safe and Effective Alternative to Medication for Acute Migraine Control?

D. Wingerchuk, Cumara B. O’Carroll, Benzion Blech, 2020, The neurologist.

Migraine With Aura Is a Risk Factor for Cardiovascular and Cerebrovascular Disease: A Critically Appraised Topic

D. Dodick, B. Demaerschalk, D. Wingerchuk, 2007, The neurologist.

Chapter 16 Neuromyelitis Optica

B. Weinshenker, D. Wingerchuk, 2003 .

Cerebrospinal Fluid Angiotensin-Converting Enzyme for Diagnosis of Central Nervous System Sarcoidosis

B. Demaerschalk, D. Wingerchuk, K. Wellik, 2009, The neurologist.

Neuromyelitis optica spectrum disorder diagnostic criteria: Sensitivity and specificity are both important

B. Weinshenker, D. Wingerchuk, 2017, Multiple sclerosis.

The Effect of Selective Serotonin Reuptake Inhibitors on the Frequency of Psychogenic Nonepileptic Seizures: A Critically Appraised Topic

B. Demaerschalk, D. Wingerchuk, K. Wellik, 2013, The neurologist.

Treatment of MOG antibody associated disorders: results of an international survey

O. Ciccarelli, S. Broadley, A. Traboulsee, 2020, Journal of Neurology.

Is Autologous Stem Cell Transplantation a Safe and Effective Alternative to Whole Brain Radiation as Consolidation Therapy in Patients With Primary Central Nervous System Lymphoma?

M. Mrugala, D. Wingerchuk, Cumara B. O’Carroll, 2021, The neurologist.

Physical Activity Level and Future Risk of Mild Cognitive Impairment or Dementia: A Critically Appraised Topic

R. Caselli, Y. Geda, B. Woodruff, 2015, The neurologist.

Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays.

B. Weinshenker, C. Lucchinetti, D. Wingerchuk, 2009, Archives of neurology.

Surgical Decompression Improves Mortality and Morbidity After Large Territory Acute Cerebral Infarction: A Critically Appraised Topic

R. Zimmerman, B. Demaerschalk, D. Wingerchuk, 2011, The neurologist.

A population-based case-control study of the tumor necrosis factor alpha-308 polymorphism in multiple sclerosis

B. Weinshenker, S. Sommer, D. Wingerchuk, 1997, Neurology.

A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis

B. Weinshenker, C. Lucchinetti, J. Noseworthy, 2005, Neurology.

Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD

B. Weinshenker, D. Wingerchuk, S. Pittock, 2022, Neurology.

Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial.

Jacqueline Palace, K. Fujihara, H. Kim, 2020, Multiple sclerosis and related disorders.

Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.

Jacqueline A Palace, D. Wingerchuk, M. Levy, 2014, JAMA neurology.

Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica

B. Weinshenker, C. Lucchinetti, C. Costanzi, 2013, Neurology.

Effects of age and sex on aquaporin-4 autoimmunity.

B. Weinshenker, J. Mandrekar, C. Lucchinetti, 2012, Archives of neurology.

Serum Neuron Specific Enolase to Predict Neurological Outcome After Cardiopulmonary Resuscitation: A Critically Appraised Topic

B. Bobrow, B. Demaerschalk, D. Wingerchuk, 2009, The neurologist.

Postinfectious encephalomyelitis

D. Wingerchuk, 2003, Current neurology and neuroscience reports.

The two faces of neuromyelitis optica

B. Weinshenker, D. Wingerchuk, 2014, Neurology.

Supplementing our understanding of vitamin D and multiple sclerosis

D. Wingerchuk, 2010, Neurology.

Is Donepezil Effective for Multiple Sclerosis-related Cognitive Dysfunction?: A Critically Appraised Topic

B. Woodruff, D. Locke, B. Demaerschalk, 2012, The neurologist.

Establishing a Diagnosis of Benign Paroxysmal Positional Vertigo Through the Dix-Hallpike and Side-Lying Maneuvers: A Critically Appraised Topic

B. Demaerschalk, D. Wingerchuk, K. Wellik, 2008, The neurologist.

Low serum vitamin D levels and recurrent inflammatory spinal cord disease.

P. Calabresi, D. Wingerchuk, S. Newsome, 2012, Archives of neurology.

Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review.

D. Wingerchuk, P. Elsbernd, J. Carter, 2020, Multiple sclerosis and related disorders.

Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder

B. Weinshenker, C. Lucchinetti, B. Lam, 2020, Neurology.

Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome.

B. Weinshenker, C. Lucchinetti, J. Bennett, 2018, American journal of ophthalmology.

Neuromyelitis optica

B. Weinshenker, D. Wingerchuk, 2006, International MS journal.

A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19

D. Wingerchuk, Cristina Valencia-Sanchez, 2020, Multiple Sclerosis and Related Disorders.

Neuroprotection as Initial Therapy in Acute Stroke

J. Ferro, M. Eliasziw, E. Wijdicks, 1998, Cerebrovascular Diseases.

Aquaporin-4 Antibodies, Neuromyelitis Optica, and Multiple Sclerosis

Frcp, D. Wingerchuk, 2007 .

IFNβ-1b may severely exacerbate Japanese opticspinal MS in neuromyelitis optica spectrum: Japanese optic-spinal MS: Is it MS or neuromyelitis optica and does the answer dictate treatment?

S. Tsuji, B. Weinshenker, R. Bomprezzi, 2011, Neurology.

Japanese optic-spinal MS

B. Weinshenker, D. Wingerchuk, 2010, Neurology.

Genetic variants in the tumor necrosis factor receptor 1 gene in patients with MS

B. Weinshenker, E. Atkinson, C. Klein, 1999, Neurology.

Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.

Aaron E Miller, B. Weinshenker, L. Krupp, 2008, Archives of neurology.

Lupus Related Longitudinal Myelitis

B. Weinshenker, D. Wingerchuk, 2011, The Journal of Rheumatology.

Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients.

B. Weinshenker, C. Lucchinetti, O. Kantarci, 2009, Archives of neurology.

Treatment of Neuromyelitis Optica With Mycophenolate Mofetil

B. Weinshenker, C. Lucchinetti, O. Kantarci, 2009 .

Acute transverse myelitis

D. Wingerchuk, B. Cree, 2005, Neurology.

White matter disease: Optimizing rituximab therapy for neuromyelitis optica

B. Weinshenker, D. Wingerchuk, 2011, Nature Reviews Neurology.

Patient management problem

D. Wingerchuk, 2008 .

Are Corticosteroids Efficacious for Preventing or Treating Neutralizing Antibodies in Multiple Sclerosis Patients Treated With Beta-Interferons?: A Critically Appraised Topic

B. Demaerschalk, D. Wingerchuk, K. Wellik, 2010, The neurologist.

Spinal cord astrocytoma presenting as “idiopathic” intracranial hypertension

M. Lyons, D. Wingerchuk, E. P. Bosch, 2006, Clinical Neurology and Neurosurgery.

Premenstrual multiple sclerosis pseudoexacerbations: Role of body temperature and prevention with aspirin.

Moses Rodriguez, D. Wingerchuk, 2006, Archives of neurology.

Acute disseminated encephalomyelitis: distinction from multiple sclerosis and treatment issues.

D. Wingerchuk, 2006, Advances in neurology.

Management of chronic central neuropathic pain following traumatic spinal cord injury.

A. Jadad, D. Wingerchuk, M. Denkers, 2001, Evidence report/technology assessment.

What is the true clinicopathologic spectrum of neuromyelitis optica?-Reply.

D. Wingerchuk, M. Levy, B. Greenberg, 2013, JAMA neurology.

requirements by permitting unilateral optic neuritis or asymptomatic brain MRI lesions

A. Traboulsee, B. Banwell, W. Carroll, 2022 .

Multiple sclerosis: epidemiology, genetics, classification, natural history, and clinical outcome measures.

B. Weinshenker, D. Wingerchuk, 2000, Neuroimaging clinics of North America.

Revised diagnostic criteria for neuromyelitis optica

B. Weinshenker, C. Lucchinetti, D. Wingerchuk, 2011, Neurology.

Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial

H. Hartung, K. Fujihara, B. Weinshenker, 2022, EBioMedicine.

Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study

F. Paul, B. Weinshenker, A. Cross, 2017, Neurology: Neuroimmunology & Neuroinflammation.

Proposed diagnostic criteria and nosology of acute transverse myelitis

L. Morrison, F. Pidcock, B. Lateur, 2003 .

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

Ichiro Nakashima, K. Fujihara, B. Weinshenker, 2004, The Lancet.

Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders

D. Wingerchuk, Cristina Valencia-Sanchez, 2020, BioDrugs.

NMO-IgG predicts the outcome of recurrent optic neuritis

B. Weinshenker, C. Lucchinetti, D. Wingerchuk, 2008, Neurology.

Neuromyelitis optica and non organ-specific autoimmunity.

Patrick Vermersch, P. Vermersch, B. Weinshenker, 2008, Archives of neurology.

The spectrum of neuromyelitis optica

B. Weinshenker, C. Lucchinetti, D. Wingerchuk, 2007, The Lancet Neurology.

Revised diagnostic criteria for neuromyelitis optica

B. Weinshenker, C. Lucchinetti, D. Wingerchuk, 2006, Neurology.

Brain abnormalities in neuromyelitis optica.

B. Weinshenker, C. Lucchinetti, D. Wingerchuk, 2006, Archives of neurology.

Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.

D. Wingerchuk, Dean M Wingerchuk, Jonathan L Carter, 2014, Mayo Clinic proceedings.

Disease modifying therapies for relapsing multiple sclerosis

B. Weinshenker, D. Wingerchuk, 2016, British Medical Journal.

Neuromyelitis optica: Changing concepts

B. Weinshenker, C. Lucchinetti, D. Wingerchuk, 2007, Journal of Neuroimmunology.

Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.

J. Parisi, B. Weinshenker, C. Lucchinetti, 2007, Brain : a journal of neurology.

The influence of smoking on multiple sclerosis and autoimmunity

D. Wingerchuk, 2012 .

INFECTIOUS AND INFLAMMATORY MYELOPATHIES

D. Wingerchuk, 2008 .

Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management

D. Wingerchuk, 2006, Expert review of neurotherapeutics.

Multiple Sclerosis: Current Pathophysiological Concepts

C. Lucchinetti, J. Noseworthy, D. Wingerchuk, 2001, Laboratory Investigation.

NMO-IgG: A Specific Biomarker for Neuromyelitis Optica

B. Weinshenker, C. Lucchinetti, D. Wingerchuk, 2006, Disease markers.

Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis.

B. Weinshenker, C. Lucchinetti, D. Wingerchuk, 2014, JAMA neurology.

Adjunctive Haloperidol Prophylaxis Reduces Postoperative Delirium Severity and Duration in At-Risk Elderly Patients

R. Caselli, B. Woodruff, B. Demaerschalk, 2008, The neurologist.

Diagnosis and Treatment of Neuromyelitis Optica

D. Wingerchuk, 2007, The neurologist.

Early versus late antiepileptic drug withdrawal for people with epilepsy in remission.

M. Sperling, J. Sirven, D. Wingerchuk, 2001, The Cochrane database of systematic reviews.

Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study

B. Weinshenker, J. Mandrekar, C. Lucchinetti, 2013, The Lancet Neurology.

Treatment of Neuromyelitis Optica: Review and Recommendations.

A. Traboulsee, K. Fujihara, E. Waubant, 2012, Multiple sclerosis and related disorders.

Evidence‐based medicine in health research

D. Wingerchuk, 2015 .

Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis

B. Weinshenker, T. Kaufmann, D. Wingerchuk, 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

Epidemiology of aquaporin‐4 autoimmunity and neuromyelitis optica spectrum

J. Sauver, B. Weinshenker, J. Mandrekar, 2016, Annals of neurology.

Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.

B. Weinshenker, C. Lucchinetti, D. Wingerchuk, 2015, JAMA neurology.

Clinical practice. Transverse myelitis.

E. Frohman, D. Wingerchuk, 2010, The New England journal of medicine.

Progressive cervical myelopathy secondary to chronic ventriculoperitoneal CSF overshunting

N. P. Patel, D. Dodick, D. Wingerchuk, 2005, Neurology.

The Role of Corticosteroids in the Management of Chronic Subdural Hematomas: A Critically Appraised Topic

B. Demaerschalk, D. Wingerchuk, M. Aguilar, 2009, The neurologist.

Positive neurologic phenomena with initiation of dalfampridine for multiple sclerosis.

D. Wingerchuk, J. Carter, Greg M Thaera, 2014, Multiple sclerosis and related disorders.

Evidence-Based Neurology: Management of Neurological Disorders: Demaerschalk/Evidence-Based Neurology: Management of Neurological Disorders

B. Demaerschalk, D. Wingerchuk, 2015 .

Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica

B. Weinshenker, C. Lucchinetti, D. Wingerchuk, 2009, Muscle & nerve.

Alpha-Lipoic Acid May Improve Symptomatic Diabetic Polyneuropathy

B. Demaerschalk, D. Wingerchuk, B. Crum, 2007, The neurologist.

Challenges and opportunities in designing clinical trials for neuromyelitis optica

J. M. Behne, Terry J. Smith, M. Sormani, 2015, Neurology.

[Transverse myelitis].

E. Frohman, D. Wingerchuk, 2010, Xianggang hu li za zhi. The Hong Kong nursing journal.

Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension.

Jacqueline Palace, K. Fujihara, M. Barnett, 2021, Multiple sclerosis and related disorders.

NEUROMYELITIS OPTICA SPECTRUM DISORDERS

D. Wingerchuk, 2010, Continuum.

Neuromyelitis optica: Effect of gender

D. Wingerchuk, 2009, Journal of the Neurological Sciences.

Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis

C. Lucchinetti, D. Wingerchuk, 2007, Current opinion in neurology.

Neuromyelitis optica: new findings on pathogenesis.

D. Wingerchuk, 2007, International review of neurobiology.

Evidence for humoral autoimmunity in neuromyelitis optica

D. Wingerchuk, 2006, Neurological research.

High risk of postpartum relapses in neuromyelitis optica spectrum disorder

F. Paul, B. Weinshenker, A. Cross, 2017, Neurology.

New-onset Atrial Fibrillation in Severe Sepsis and Risk of Stroke and Death: A Critically Appraised Topic

F. Tondato, B. Demaerschalk, D. Wingerchuk, 2012, The neurologist.

IVIG Versus PLEX in the Treatment of Worsening Myasthenia Gravis: What is the Evidence? A Critically Appraised Topic

B. Demaerschalk, D. Wingerchuk, K. Wellik, 2015, The neurologist.

Current Evidence and Therapeutic Strategies for Multiple Sclerosis

D. Wingerchuk, Dean Wingerchuk1, 2008, Seminars in neurology.

Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.

Jacqueline Palace, K. Fujihara, H. Kim, 2019, The New England journal of medicine.

Immune-Mediated Myelopathies

D. Wingerchuk, 2018, Continuum.

Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 IgG‐Positive NMOSD

Jacqueline Palace, K. Fujihara, H. Kim, 2021, Annals of neurology.

Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide

J. M. Behne, Jacqueline Palace, S. Broadley, 2020, Frontiers in Neurology.

Risk of Development of Medication Overuse Headache With Nonsteroidal Anti-inflammatory Drug Therapy for Migraine: A Critically Appraised Topic

D. Dodick, B. Demaerschalk, D. Wingerchuk, 2011, The neurologist.

Cannabis for medical purposes: cultivating science, weeding out the fiction

D. Wingerchuk, 2004, The Lancet.

Disease-modifying therapies should be stopped in NMOSD patients in remission – Commentary

D. Wingerchuk, 2019, Multiple sclerosis.

Randomized controlled trials to assess therapies for multiple sclerosis

J. Noseworthy, D. Wingerchuk, 2002, Neurology.

Is Dabigatran Cost Effective Compared With Warfarin for Stroke Prevention in Atrial Fibrillation?: A Critically Appraised Topic

B. Demaerschalk, D. Wingerchuk, M. Aguilar, 2012, The neurologist.

Is Obstructive Sleep Apnea an Independent Risk Factor for Stroke?: A Critically Appraised Topic

J. Parish, C. Snyder, B. Demaerschalk, 2010, The neurologist.

What is the Effect of Low-molecular Weight Heparin for Venous Thromboembolism Prophylaxis Compared With Mechanical Methods, on the Occurrence of Hemorrhagic and Venous Thromboembolic Complications in Patients With Intracerebral Hemorrhage?: A Critically Appraised Topic

B. Demaerschalk, D. Wingerchuk, Cumara B. O’Carroll, 2011, The neurologist.

Safety and Efficacy of Ultrasound-enhanced Thrombolysis in the Treatment of Acute Middle Cerebral Artery Infarction: A Critically Appraised Topic

B. Demaerschalk, D. Wingerchuk, M. Aguilar, 2011, The Neurologist.

Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder

F. Paul, K. Fujihara, D. Wingerchuk, 2021, Neurology and Therapy.

Treatment of Vascular Dementia and Vascular Cognitive Impairment

B. Demaerschalk, D. Wingerchuk, 2007, The neurologist.

Multiple Sclerosis: The History of a Disease

D. Wingerchuk, 2005 .

The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease.

J. Baskerville, G. Rice, G. Ebers, 2006, Brain : a journal of neurology.

The contemporary spectrum of multiple sclerosis misdiagnosis

Gregory F. Wu, B. Weinshenker, A. Cross, 2016, Neurology.

Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes

Jacqueline Palace, F. Paul, A. Chaudhuri, 2015, Journal of Neurology.

Clinical Predictors of Psychogenic Nonepileptic Seizures: A Critically Appraised Topic

J. Sirven, J. Drazkowski, B. Demaerschalk, 2008, The neurologist.

Do Cannabinoids Reduce Multiple Sclerosis-Related Spasticity?

B. Demaerschalk, D. Wingerchuk, K. Wellik, 2009, The neurologist.

Clinical outcome measures and rating scales in multiple sclerosis trials.

B. Weinshenker, J. Noseworthy, D. Wingerchuk, 1997, Mayo Clinic proceedings.

Neuromyelitis optica (Devic's syndrome).

B. Weinshenker, D. Wingerchuk, 2014, Handbook of clinical neurology.

Evaluation of aquaporin‐4 antibody assays

B. Weinshenker, J. Bennett, D. Wingerchuk, 2014, Clinical & experimental neuroimmunology.

Therapeutic Hypothermia for Severe Traumatic Brain Injury: A Critically Appraised Topic

W. Freeman, B. Demaerschalk, D. Wingerchuk, 2012, The neurologist.

Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS

B. Weinshenker, D. Wingerchuk, J. Corboy, 2018, Neurology.

Serum Neurofilament to Magnetic Resonance Imaging Lesion Area Ratio Differentiates Spinal Cord Infarction From Acute Myelitis.

Serena Zanzoni, A. Rabinstein, D. Wingerchuk, 2021, Stroke.

Effectiveness of Adding Memantine to an Alzheimer Dementia Treatment Regimen Which Already Includes Stable Donepezil Therapy: A Critically Appraised Topic

R. Caselli, B. Demaerschalk, D. Wingerchuk, 2011, The neurologist.

Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder.

Larissa A. Jarzylo, B. Weinshenker, D. Wingerchuk, 2022, Journal of managed care & specialty pharmacy.

Current Disease-Modifying Therapeutic Strategies in Multiple Sclerosis

D. Wingerchuk, A. Jacob, 2010 .

Aspirin is Unlikely to Have A Clinically Meaningful Effect on Multiple Sclerosis-Related Fatigue: Data From a Randomized Controlled Trial (P7.245)

Moses Rodriguez, M. Keegan, D. Wingerchuk, 2014 .

NEDA treatment target? No evident disease activity as an actionable outcome in practice

C. Lucchinetti, D. Wingerchuk, E. Flanagan, 2017, Journal of the Neurological Sciences.

Autonomic symptom burden is associated with MS-related fatigue and quality of life.

D. Wingerchuk, J. Carter, B. Goodman, 2015, Multiple sclerosis and related disorders.

Not every patient with multiple sclerosis should be treated at time of diagnosis.

B. Weinshenker, C. Lucchinetti, Moses Rodriguez, 2006, Archives of neurology.

Timing of Antiepileptic Drug Withdrawal in Adult Epilepsy Patients After Neocortical Surgical Resection: A Critically Appraised Topic

B. Demaerschalk, K. Noe, D. Wingerchuk, 2011, The neurologist.

Early versus late antiepileptic drug withdrawal for people with epilepsy in remission.

M. Sperling, S. Nolan, J. Sirven, 2015, The Cochrane database of systematic reviews.

AQP4 autoantibody assay performance in clinical laboratory service

B. Weinshenker, C. Lucchinetti, D. Wingerchuk, 2014, Neurology: Neuroimmunology & Neuroinflammation.

Is Intravenous Immunoglobulin Effective in Reducing the Risk of Mortality and Morbidity in Neuroinvasive West Nile Virus Infection?

D. Wingerchuk, Cumara B. O’Carroll, Lisa A. Marks, 2022, The neurologist.

The effects of monoamine oxidase B inhibition on dopamine metabolism in rats with nigro-striatal lesions

E. Scarr, D. Wingerchuk, A. Juorio, 1994, Neurochemical Research.

Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders

B. Weinshenker, John J. Chen, J. Mills, 2021, Multiple sclerosis journal - experimental, translational and clinical.

CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies

E. Wijdicks, B. Weinshenker, John J. Chen, 2021, Neurology.

OSMS is NMO, but not MS: proven clinically and pathologically

K. Fujihara, B. Weinshenker, D. Wingerchuk, 2006, The Lancet Neurology.

Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder

K. Fujihara, B. Weinshenker, J. Bennett, 2023, Journal of Neurology, Neurosurgery, and Psychiatry.

A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder

Jacqueline Palace, D. Wingerchuk, S. Pittock, 2023, Frontiers in Neurology.

Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients With Myelin Oligodendrocyte Glycoprotein IgG-Associated Disorders.

B. Weinshenker, John J. Chen, D. Wingerchuk, 2020, JAMA neurology.

Cerebral enhancement in MOG antibody-associated disease

J. Tillema, D. Wingerchuk, P. Morris, 2023, Journal of neurology, neurosurgery, and psychiatry.

Telemedicine Versus Telephone for Remote Emergency Stroke Consultations: A Critically Appraised Topic

T. Ingall, B. Bobrow, B. Demaerschalk, 2009, The neurologist.

Disrupted Daytime Activity and Altered Sleep-Wake Patterns May Predict Transition to Mild Cognitive Impairment or Dementia: A Critically Appraised Topic

R. Caselli, B. Woodruff, B. Demaerschalk, 2012, The neurologist.

In Patients With Functional Movement Disorders, Is Specialized Physical Therapy Effective in Improving Motor Symptoms?

S. Mehta, D. Wingerchuk, Cumara B. O’Carroll, 2022, The neurologist.

A Response to: Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder”

K. Fujihara, D. Wingerchuk, S. Pittock, 2022, Neurology and Therapy.

Is Intravenous Thrombolysis Safe and Effective in Central Retinal Artery Occlusion? A Critically Appraised Topic

M. Kurli, B. Demaerschalk, D. Wingerchuk, 2017, The neurologist.

The natural history of multiple sclerosis: implications for trial design.

B. Weinshenker, D. Wingerchuk, 1999, Current opinion in neurology.

A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis

W. K. Peterson, B. Weinshenker, J. Noseworthy, 2001, Neurology.

Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder

F. Paul, H. Hartung, F. Lublin, 2021, Neurology: Neuroimmunology & Neuroinflammation.

Placebo-controlled study in neuromyelitis optica—Ethical and design considerations

Jeffrey A. Cohen, K. Patra, F. Paul, 2015, Multiple sclerosis.

Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders

D. Wingerchuk, Cristina Valencia-Sanchez, 2020, BioDrugs.

Neuromyelitis Optica: Potential Roles for Intravenous Immunoglobulin

D. Wingerchuk, 2012, Journal of Clinical Immunology.

Neuromyelitis optica: current concepts.

D. Wingerchuk, 2004, Frontiers in bioscience : a journal and virtual library.

Characterization of Disease Severity and Stability in NMOSD: A Global Clinical Record Review with Patient Interviews

D. Wingerchuk, M. Ringelstein, M. Capobianco, 2023, Neurology and Therapy.

A Combination Trial of Estriol Plus Glatimer Acetate in Relapsing-Remitting Multiple Sclerosis (I7-2.002)

R. Elashoff, Angela Bates, N. Sicotte, 2014 .

Understanding Treatment Decisions in Neuromyelitis Optica Spectrum Disorder: A Global Clinical Record Review with Patient Interviews

D. Wingerchuk, M. Ringelstein, M. Capobianco, 2023, Neurology and Therapy.

Revised Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders (S63.001)

A. Traboulsee, B. Banwell, W. Carroll, 2014 .

Systematic Review Investigating Relationship Between Neuromyelitis Optica Spectrum Disorder (NMOSD) and Vaccination (P1.2-003)

D. Wingerchuk, Aimen Vanood, 2019 .

A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis

W. K. Peterson, B. Weinshenker, Moses Rodriguez, 2001, Neurology.

The clinical course of acute disseminated encephalomyelitis

D. Wingerchuk, 2006, Neurological research.

Denaturation fingerprinting: two related mutation detection methods especially advantageous for high G + C regions.

B. Weinshenker, D. Wingerchuk, S. Sommer, 1998, BioTechniques.

Acute Therapies and Disease-Modifying Therapies for Multiple Sclerosis

D. Wingerchuk, K. Bashir, 2012 .

Alterations in Aquaporin‐4‐IgG Serostatus in 986 Patients: A Laboratory‐Based Longitudinal Analysis

B. Weinshenker, J. Bennett, J. Mills, 2023, Annals of neurology.

Efficacy of Rivastigmine for Cognitive Symptoms in Parkinson Disease With Dementia

C. Adler, R. Caselli, J. Caviness, 2009, The neurologist.

Therapies for multiple sclerosis

D. Wingerchuk, Greg M Thaera, 2015 .

Reversible Cerebral Vasculopathy, Transverse Myelitis, and Active Systemic Lupus Erythematosus in an Aquaporin-4 Antibody–Positive Patient

D. Wingerchuk, B. Chong, A. Mbonde, 2021, Neurology: Neuroimmunology & Neuroinflammation.

Determination of Hemispheric Language Dominance in the Surgical Epilepsy Patient: Diagnostic Properties of Functional Magnetic Resonance Imaging

Bart M Demaerschalk, R. Zimmerman, B. Demaerschalk, 2012, The neurologist.

What is Clinical Efficacy of Transesophageal Echocardiography in Patients With Cryptogenic Stroke?: A Critically Appraised Topic

B. Demaerschalk, D. Wingerchuk, Cumara B. O’Carroll, 2018, The neurologist.

Are Corticosteroid and Antiviral Treatments Effective for Bell Palsy?: A Critically Appraised Topic

B. Demaerschalk, D. Wingerchuk, K. Wellik, 2010, The neurologist.

Anticonvulsant Drug Therapy After Aneurysmal Subarachnoid Hemorrhage: A Critically Appraised Topic

R. Zimmerman, J. Sirven, B. Demaerschalk, 2010, The neurologist.

Do Antiepileptic Drugs Increase the Risk of Suicidality in Adult Patients With Epilepsy?: A Critically Appraised Topic

J. Drazkowski, B. Demaerschalk, D. Wingerchuk, 2010, The neurologist.

EXPERT OPINIONS ON THE DIAGNOSIS AND TREATMENT OF PATIENTS WITH AQP4-NEGATIVE NMO/MS OVERLAPPING SYNDROMES

A. Chaudhuri, B. Weinshenker, D. Wingerchuk, 2015, Journal of Neurology, Neurosurgery & Psychiatry.

Restoring immune tolerance in neuromyelitis optica

J. M. Behne, Terry J. Smith, Jacqueline Palace, 2016, Neurology: Neuroimmunology & Neuroinflammation.

Acute Disseminated Encephalomyelitis, Transverse Myelitis, and Neuromyelitis Optica

B. Weinshenker, D. Wingerchuk, 2013, Continuum.

Acute transverse myelitis

F. Pidcock, D. Kerr, D. Wingerchuk, 2005, Neurology.

Revised diagnostic criteria for neuromyelitis optica

B. Weinshenker, C. Lucchinetti, D. Wingerchuk, 2006, Neurology.

Transverse Myelitis

E. Frohman, D. Wingerchuk, Gunawan Budiarto, 2009 .

Neuromyelitis optica

B. Weinshenker, D. Wingerchuk, M. Matiello, 2007, Current opinion in neurology.

Neuromyelitis optica (Devic's syndrome).

B. Weinshenker, D. Wingerchuk, 2014, Handbook of clinical neurology.

Neuromyelitis optica.

D. Wingerchuk, 2006, International MS journal.

Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis.

B. Weinshenker, C. Lucchinetti, D. Wingerchuk, 2014, JAMA neurology.

Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.

Jacqueline A Palace, D. Wingerchuk, M. Levy, 2014, JAMA neurology.

Are Corticosteroid and Antiviral Treatments Effective for Bell Palsy?: A Critically Appraised Topic

B. Demaerschalk, D. Wingerchuk, K. Wellik, 2010, The Neurologist.

A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing–remitting multiple sclerosis

G. Rice, G. Ebers, D. Wingerchuk, 2005, Journal of Neurology, Neurosurgery & Psychiatry.

Do Cannabinoids Reduce Multiple Sclerosis-Related Spasticity?

B. Demaerschalk, D. Wingerchuk, K. Wellik, 2009, The neurologist.

Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial

B. Weinshenker, D. Wingerchuk, S. Pittock, 2024, The Lancet Neurology.